|
| 37956738 | Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201. | Ann Oncol | 2024 |
| 37556096 | Case-control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study. | Clin Transl Oncol | 2024 |
| 36708371 | Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03. | Clin Transl Oncol | 2023 |
| 37143685 | Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution. | Front Immunol | 2023 |
| 37101768 | Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. | Eur Urol Open Sci | 2023 |
| 37293154 | <i>PBRM1</i> and <i>KDM5C</i> cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer. | Am J Cancer Res | 2023 |
| 34782936 | MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. | Virchows Arch | 2022 |
| 35740506 | Genome-Wide Meta-Analysis Identifies Variants in <i>DSCAM</i> and <i>PDLIM3</i> That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. | Cancers (Basel) | 2022 |
| 35405437 | Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy. | ESMO Open | 2022 |
| 35428584 | Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group. | Clin Genitourin Cancer | 2022 |
| 35994225 | MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer. | Clin Transl Oncol | 2022 |
| 35956100 | Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients. | J Clin Med | 2022 |
| 33442023 | Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma. | Genet Med | 2021 |
| 33556897 | Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). | ESMO Open | 2021 |
| 34944855 | Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma. | Cancers (Basel) | 2021 |
| 34893524 | Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. | J Immunother Cancer | 2021 |
| 34549539 | Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. | Cancer Med | 2021 |
| 34103386 | Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. | Int J Gynecol Cancer | 2021 |
| 31335987 | PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. | Int J Cancer | 2020 |
| 32081561 | MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer. | Urol Oncol | 2020 |
| 32861537 | The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. | Gynecol Oncol | 2020 |
| 32915890 | MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. | PLoS One | 2020 |
| 32616874 | Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. | Mod Pathol | 2020 |
| 32840418 | Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. | J Clin Oncol | 2020 |
| 32554541 | Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). | Clin Cancer Res | 2020 |
| 32473302 | Prognostic gene expression signature for high-grade serous ovarian cancer. | Ann Oncol | 2020 |
| 32359490 | Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. | Lancet Oncol | 2020 |
| 32565133 | Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma. | Clin Genitourin Cancer | 2020 |
| 32495160 | Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. | Target Oncol | 2020 |
| 30470691 | Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy. | Oncologist | 2019 |
| 31340094 | Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. | N Engl J Med | 2019 |
| 31562800 | Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. | N Engl J Med | 2019 |
| 28535693 | Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies. | Expert Opin Drug Saf | 2018 |
| 30062862 | Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. | J Pathol Clin Res | 2018 |
| 29697920 | Metastatic Prostate Cancer. | N Engl J Med | 2018 |
| 29490989 | A Genetic Polymorphism in <i>CTLA-4</i> Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma. | Clin Cancer Res | 2018 |
| 29232987 | Radium-223 international early access program: results from the Spanish subset. | Future Oncol | 2018 |
| 26810136 | Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. | Pharmacogenomics J | 2017 |
| 28088073 | Strategies to design clinical studies to identify predictive biomarkers in cancer research. | Cancer Treat Rev | 2017 |
| 28389316 | Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. | Lancet Oncol | 2017 |
| 28385611 | Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity. | Urol Oncol | 2017 |
| 28430711 | Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. | Pharmacogenet Genomics | 2017 |
| 29049607 | Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. | JAMA Oncol | 2017 |
| 29118224 | Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel <i>MTOR</i>-Activating Mutation. | J Natl Compr Canc Netw | 2017 |
| 28916367 | Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2017 |
| 28753791 | A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01). | Eur Urol Focus | 2017 |
| 28864728 | mTOR Pathway Mutations and Response to Rapalogs in RCC-Letter. | Clin Cancer Res | 2017 |
| 27901483 | Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients. | Oncotarget | 2017 |
| 27582484 | Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. | Clin Cancer Res | 2017 |
| 26169213 | Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma. | Clin Transl Oncol | 2016 |